Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis

About this update from Soligenix, Inc.

[{"type":"text","content":"Enrollment on Track to Begin in 4th Quarter of 2022\nPRINCETON, N.J., June 28, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial titled, \"Phase 2 Study Evaluating SGX302 in the Treatment of Mild-to-Moderate Psoriasis.\" The study is designed to evaluate the safety and efficacy of topically-applied SGX302 (synthetic hypericin) and is expected to begin patient enrollment in the fourth quarter of 2022.\n\"We are pleased to have received FDA clearance on our SGX302 Phase 2a clinical trial in mild-to-moderate psoriasis,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \"During the last year, we have made announcements of important development milestones that we have achieved with HyBryte™ (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL). We have clearly validated synthetic hypericin's biologic activity with the Phase 3 FLASH study in this orphan disease, where we expect to file a New Drug Application (NDA) in the second half of 2022. We are excited to expand synthetic hypericin's development into different cutaneous T-cell diseases such as psoriasis, as a component of our long-term strategy to enhance the value of this unique compound. Psoriasis is an ongoing unmet medical need, with as many as 7.5 million people in the U.S. and 60-125 million people worldwide affected by this incurable disease. Given our promising results with hypericin to date, including a small Phase 1/2 proof of concept clinical trial in mild-to-moderate psoriasis, we are hopeful synthetic hypericin will have a role to play in helping patients suffering from this difficult to treat and chronic disease.\"\nUnder this IND, the Phase 2a clinical trial of SGX302 will be a randomized, double-blind, placebo-controlled study that will enroll up to 32 patients age 18 years or older with mild to moderate, stable psoriasis covering 2 to 30% of their body. Patients will receive placebo or SGX302 (randomized 1:1) as a twice weekly treatment for up to 18 weeks. Each tr...

More updates from Soligenix, Inc.